

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884

**DECLARATION OF KIRA A. DAVIS IN SUPPORT OF
MOTION FOR ADMISSION *PRO HAC VICE***

I, Kira A. Davis, declare as follows:

1. I am an attorney licensed to practice law in the states of New York and California and am admitted to practice before the United States Court of Appeals for the Federal Circuit. I am also admitted to practice before the United States Court of Appeals for the Second Circuit, the United States Court of Appeals for the Sixth Circuit, and the United States District Courts for the Southern District of New York, the Eastern District of New York, the Northern District of California, and the Central District of California.

2. I am a member in good standing in all jurisdictions where I have been admitted to practice.

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. I have never had an application denied for admission before any court or administrative body.

5. I have never had any sanctions or contempt citations imposed by any court or administrative body.

6. I have read and agree to comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in 37 C.F.R. part 42.

7. I affirm my agreement before the USPTO to be subject to the USPTO Rules of Professional Conduct 37 C.F.R. §§ 11.101 *et seq.* and disciplinary

jurisdiction under 37 C.F.R. § 11.19(a).

8. I have applied to appear *pro hac vice* in the following proceedings before the USPTO in the last three (3) years:

a. *Celltrion Inc. v. Regeneron Pharmaceuticals Inc.*, IPR2023-00462
(*pro hac vice* granted).

b. *Samsung Bioepis Co., LTD v. Regeneron Pharmaceuticals Inc.*,
IPR2023-00739 (*pro hac vice* pending).

9. I have been a partner at the law firm of Morrison & Foerster LLP since I joined the firm on January 1, 2023. I was previously a partner at the law firm of Durie Tangri LLP, from July 1, 2020 through December 31, 2022. Prior to that I was employed at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison LLP. I have worked on patent litigation matters, and particularly, patent litigation matters relating to biotechnology, for approximately 12 years. Over my twelve years working on patent litigation matters, I have handled many patent cases relating to methods of treatment using biologic therapeutics, including fusion proteins and antibodies.

10. I am familiar with the subject matter at issue in this proceeding. I have been engaged by the Patent Owner to represent the Patent Owner before the Board in this proceeding. I have undertaken the study of *inter alia* the '572 Patent, the Petition for *Inter Partes* Review, and the art cited in the Petition. I am also

familiar with the co-pending litigations identified by the Petitioner in the Petition for *Inter Partes* Review, Paper 2 at 6. I have represented Patent Owner in patent matters relating to Eylea® since September 2022. I have acquired a substantial understanding of the underlying legal and technological issues at stake in these proceedings.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of U.S. Patent No. 11,253,572.

Dated: December 20, 2023

By: /Kira A. Davis/
Kira A. Davis
MORRISON & FOERSTER LLP
707 Wilshire Boulevard, Suite 6000
Los Angeles, CA 90017
Tel: (213) 892-5654